Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Background

Gastric cancer (GC) has a poor prognosis because it is highly aggressive, yet there are currently few effective therapies available. Although protein ubiquitination has been shown to play a complex role in the development of gastric cancer, to date, no efficient ubiquitinating enzymes have been identified as treatment targets for GC.

Methods

The TCGA database was used for bioinformatic investigation of ubiquitin-specific protease 31 (USP31) expression in GC, and experimental techniques, including Western blotting, qRT-PCR, and immunohistochemistry, were used to confirm the findings. We also analyzed the relationship between USP31 expression and clinical prognosis in patients with GC. We further investigated the effects of USP31 on the proliferation, invasion, migration, and glycolysis of GC cells and by using colony formation, CCK-8 assays, Transwell chamber assays, cell scratch assays, and cell-derived xenograft. Furthermore, we examined the molecular processes by which USP31 influences the biological development of GC.

Results

Patients with high USP31 expression have a poor prognosis because USP31 is abundantly expressed in GC. Therefore, USP31 reduces the level of ubiquitination of the Wnt/β-catenin pathway by binding to β-catenin, thereby activating glycolysis, which ultimately promotes GC proliferation and aggressive metastasis.

Conclusion

USP31 inhibits ubiquitination of β-catenin by binding to it, stimulates the Wnt/β-catenin pathway, activates glycolysis, and accelerates the biology of GCs, which are all demonstrated in this work.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928297343240425055552
2025-04-01
2025-11-04

  • From This Site

    /content/journals/pra/10.2174/0115748928297343240425055552
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. ChenZ-S. LinL-Z. ZhangS-X. LiuW. AiB. SunL-L. Current advances and outlook in gastric cancer chemoresistance: A review.Recent Patents Anticancer Drug Discov.2022171264110.2174/157489281666621092916572934587888
     [Google Scholar]
  3. ChenZ ChengG. Fatty Acid metabolism signature contributes to the molecular diagnosis of a malignant gastric cancer subtype with poor prognosis and lower mutation burden.Recent Pat Anticancer Drug Discov202310.2174/1574892819666230907145036
     [Google Scholar]
  4. FerlayJ. ColombetM. SoerjomataramI. ParkinD.M. PiñerosM. ZnaorA. BrayF. Cancer statistics for the year 2020: An overview.Int. J. Cancer2021149477878910.1002/ijc.3358833818764
     [Google Scholar]
  5. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  6. GuoG ZhouZ ChenS Characterization of the prognosis and tumor microenvironment of cellular senescence-related genes through scRNA-Seq and bulk RNA-Seq analysis in GC.Recent Pat Anticancer Drug Discov.202310.2174/0115748928255417230924191157
     [Google Scholar]
  7. FitzmauriceC. AbateD. AbbasiN. AbbastabarH. Abd-AllahF. Abdel-RahmanO. AbdelalimA. AbdoliA. AbdollahpourI. AbdulleA.S.M. AbebeN.D. AbrahaH.N. Abu-RaddadL.J. AbualhasanA. AdedejiI.A. AdvaniS.M. AfaridehM. AfshariM. AghaaliM. AgiusD. AgrawalS. AhmadiA. AhmadianE. AhmadpourE. AhmedM.B. AkbariM.E. AkinyemijuT. Al-AlyZ. AlAbdulKaderA.M. AlahdabF. AlamT. AlameneG.M. AlemnewB.T.T. AleneK.A. AliniaC. AlipourV. AljunidS.M. BakesheiF.A. AlmadiM.A.H. Almasi-HashianiA. AlsharifU. AlsowaidiS. Alvis-GuzmanN. AminiE. AminiS. AmoakoY.A. AnbariZ. AnberN.H. AndreiC.L. AnjomshoaM. AnsariF. AnsariadiA. AppiahS.C.Y. Arab-ZozaniM. ArablooJ. ArefiZ. AremuO. AreriH.A. ArtamanA. AsayeshH. AsfawE.T. AshagreA.F. AssadiR. AtaeiniaB. AtalayH.T. AtaroZ. AtiqueS. AusloosM. Avila-BurgosL. AvokpahoE.F.G.A. AwasthiA. AwokeN. Ayala QuintanillaB.P. AyanoreM.A. AyeleH.T. BabaeeE. BachaU. BadawiA. BagherzadehM. BagliE. BalakrishnanS. BalouchiA. BärnighausenT.W. BattistaR.J. BehzadifarM. BehzadifarM. BekeleB.B. BelayY.B. BelaynehY.M. BerfieldK.K.S. BerhaneA. BernabeE. BeuranM. BhaktaN. BhattacharyyaK. BiadgoB. BijaniA. Bin SayeedM.S. BirungiC. BisignanoC. BitewH. BjørgeT. BleyerA. BogaleK.A. BojiaH.A. BorzìA.M. BosettiC. Bou-OrmI.R. BrennerH. BrewerJ.D. BrikoA.N. BrikoN.I. Bustamante-TeixeiraM.T. ButtZ.A. CarrerasG. CarreroJ.J. CarvalhoF. CastroC. CastroF. Catalá-LópezF. CerinE. ChaiahY. ChanieW.F. ChattuV.K. ChaturvediP. ChauhanN.S. ChehraziM. ChiangP.P.C. ChichiabelluT.Y. Chido-AmajuoyiO.G. Chimed-OchirO. ChoiJ.Y.J. ChristopherD.J. ChuD.T. ConstantinM.M. CostaV.M. CrocettiE. CroweC.S. CuradoM.P. DahlawiS.M.A. DamianiG. DarwishA.H. DaryaniA. das NevesJ. DemekeF.M. DemisA.B. DemissieB.W. DemozG.T. Denova-GutiérrezE. DerakhshaniA. DeribeK.S. DesaiR. DesalegnB.B. DestaM. DeyS. DharmaratneS.D. DhimalM. DiazD. DinberuM.T.T. DjalaliniaS. DokuD.T. DrakeT.M. DubeyM. DubljaninE. DukenE.E. EbrahimiH. EffiongA. EftekhariA. El SayedI. ZakiM.E.S. El-JaafaryS.I. El-KhatibZ. EleminehD.A. ElkoutH. EllenbogenR.G. ElsharkawyA. EmamianM.H. EndalewD.A. EndriesA.Y. EshratiB. FadhilI. Fallah OmraniV. FaramarziM. FarhangiM.A. FarioliA. FarzadfarF. FentahunN. FernandesE. FeyissaG.T. FilipI. FischerF. FisherJ.L. ForceL.M. ForoutanM. FreitasM. FukumotoT. FutranN.D. GallusS. GankpeF.G. GayesaR.T. GebrehiwotT.T. GebremeskelG.G. GedefawG.A. GelawB.K. GetaB. GetachewS. GezaeK.E. GhafourifardM. GhajarA. GhashghaeeA. GholamianA. GillP.S. GinindzaT.T.G. GirmayA. GizawM. GomezR.S. GopalaniS.V. GoriniG. GoulartB.N.G. GradaA. Ribeiro GuerraM. GuimaraesA.L.S. GuptaP.C. GuptaR. HadkhaleK. Haj-MirzaianA. Haj-MirzaianA. HamadehR.R. HamidiS. HanforeL.K. HaroJ.M. HasankhaniM. HasanzadehA. HassenH.Y. HayR.J. HayS.I. HenokA. HenryN.J. HerteliuC. HidruH.D. HoangC.L. HoleM.K. HoogarP. HoritaN. HosgoodH.D. HosseiniM. HosseinzadehM. HostiucM. HostiucS. HousehM. HussenM.M. IleanuB. IlicM.D. InnosK. IrvaniS.S.N. IsehK.R. IslamS.M.S. IslamiF. Jafari BalalamiN. JafariniaM. JahangiryL. JahaniM.A. JahanmehrN. JakovljevicM. JamesS.L. JavanbakhtM. JayaramanS. JeeS.H. JenabiE. JhaR.P. JonasJ.B. JonnagaddalaJ. JooT. JungariS.B. JürissonM. KabirA. KamangarF. KarchA. KarimiN. KarimianA. KasaeianA. KasahunG.G. KassaB. KassaT.D. KassawM.W. KaulA. KeiyoroP.N. KelboreA.G. KerboA.A. KhaderY.S. KhalilarjmandiM. KhanE.A. KhanG. KhangY.H. KhatabK. KhaterA. KhayamzadehM. Khazaee-PoolM. KhazaeiS. KhojaA.T. KhosraviM.H. KhubchandaniJ. KianipourN. KimD. KimY.J. KisaA. KisaS. Kissimova-SkarbekK. KomakiH. KoyanagiA. KrohnK.J. BicerB.K. KugbeyN. KumarV. KuupielD. La VecchiaC. LadD.P. LakeE.A. LakewA.M. LalD.K. LamiF.H. LanQ. LasradoS. LauriolaP. LazarusJ.V. LeighJ. LeshargieC.T. LiaoY. LimenihM.A. ListlS. LopezA.D. LopukhovP.D. LuneviciusR. MadadinM. MagdeldinS. El RazekH.M.A. MajeedA. MalekiA. MalekzadehR. ManafiA. ManafiN. ManamoW.A. MansourianM. MansourniaM.A. MantovaniL.G. MaroufizadehS. MartiniS.M.S. Mashamba-ThompsonT.P. MassenburgB.B. MaswabiM.T. MathurM.R. McAlindenC. McKeeM. MeheretuH.A.A. MehrotraR. MehtaV. MeierT. MelakuY.A. MelesG.G. MelesH.G. MeleseA. MelkuM. MemiahP.T.N. MendozaW. MenezesR.G. MeratS. MeretojaT.J. MestrovicT. MiazgowskiB. MiazgowskiT. MihretieK.M.M. MillerT.R. MillsE.J. MirS.M. MirzaeiH. MirzaeiH.R. MishraR. MoazenB. MohammadD.K. MohammadK.A. MohammadY. DarweshA.M. MohammadbeigiA. MohammadiH. MohammadiM. MohammadianM. Mohammadian-HafshejaniA. Mohammadoo-KhorasaniM. MohammadpourhodkiR. MohammedA.S. MohammedJ.A. MohammedS. MohebiF. MokdadA.H. MonastaL. MoodleyY. MoosazadehM. MoossaviM. MoradiG. Moradi-JooM. Moradi-LakehM. MoradpourF. MorawskaL. Morgado-da-CostaJ. MorisakiN. MorrisonS.D. MosapourA. MousaviS.M. MucheA.A. MuhammedO.S.S. MusaJ. NabhanA.F. NaderiM. NagarajanA.J. NagelG. NahvijouA. NaikG. NajafiF. NaldiL. NamH.S. NasiriN. NazariJ. NegoiI. NeupaneS. NewcombP.A. NggadaH.A. NgunjiriJ.W. NguyenC.T. NikniazL. NingrumD.N.A. NirayoY.L. NixonM.R. NnajiC.A. NojomiM. NosratnejadS. ShiadehM.N. ObsaM.S. Ofori-AsensoR. OgboF.A. OhI.H. OlagunjuA.T. OlagunjuT.O. OluwasanuM.M. OmonisiA.E. OnwujekweO.E. OommenA.M. OrenE. Ortega-AltamiranoD.D.V. OtaE. OtstavnovS.S. OwolabiM.O. P AM. PadubidriJ.R. PakhaleS. PakpourA.H. PanaA. ParkE.K. ParsianH. PashaeiT. PatelS. PatilS.T. PenniniA. PereiraD.M. PiccinelliC. PillayJ.D. PirestaniM. PishgarF. PostmaM.J. PourjafarH. PourmalekF. PourshamsA. PrakashS. PrasadN. QorbaniM. RabieeM. RabieeN. RadfarA. RafieiA. RahimF. RahimiM. RahmanM.A. RajatiF. RanaS.M. RaoofiS. RathG.K. RawafD.L. RawafS. ReinerR.C. RenzahoA.M.N. RezaeiN. RezapourA. RibeiroA.I. RibeiroD. RonfaniL. RoroE.M. RoshandelG. RostamiA. SaadR.S. SabbaghP. SabourS. SaddikB. SafiriS. SahebkarA. SalahshoorM.R. SalehiF. SalemH. SalemM.R. SalimzadehH. SalomonJ.A. SamyA.M. SanabriaJ. Santric MilicevicM.M. SartoriusB. SarveazadA. SathianB. SatpathyM. SavicM. SawhneyM. SayyahM. SchneiderI.J.C. SchöttkerB. SekerijaM. SepanlouS.G. SepehrimaneshM. SeyedmousaviS. ShaahmadiF. ShabaninejadH. ShahbazM. ShaikhM.A. ShamshirianA. ShamsizadehM. SharafiH. SharafiZ. SharifM. SharifiA. SharifiH. SharmaR. SheikhA. ShirkoohiR. ShuklaS.R. SiS. SiabaniS. SilvaD.A.S. SilveiraD.G.A. SinghA. SinghJ.A. SisayS. SitasF. SobngwiE. SoofiM. SorianoJ.B. StathopoulouV. SufiyanM.B. Tabarés-SeisdedosR. TabuchiT. TakahashiK. TamtajiO.R. TarawnehM.R. TassewS.G. TaymooriP. Tehrani-BanihashemiA. TemsahM.H. TemsahO. TesfayB.E. TesfayF.H. TeshaleM.Y. TessemaG.A. ThapaS. TlayeK.G. Topor-MadryR. Tovani-PaloneM.R. TrainiE. TranB.X. TranK.B. TsadikA.G. UllahI. UthmanO.A. VacanteM. VaeziM. Varona PérezP. VeisaniY. VidaleS. ViolanteF.S. VlassovV. VollsetS.E. VosT. VosoughiK. VuG.T. VujcicI.S. WabingaH. WachamoT.M. WagnewF.S. WaheedY. WeldegebrealF. WeldesamuelG.T. WijeratneT. WondafrashD.Z. WondeT.E. WondmienehA.B. WorkieH.M. YadavR. YadegarA. YadollahpourA. YaseriM. Yazdi-FeyzabadiV. YeshanehA. YimamM.A. YimerE.M. YismaE. YonemotoN. YounisM.Z. YousefiB. YousefifardM. YuC. ZabehE. ZadnikV. MoghadamT.Z. ZaidiZ. ZamaniM. ZandianH. ZangenehA. ZakiL. ZendehdelK. ZenebeZ.M. ZewaleT.A. ZiapourA. ZodpeyS. MurrayC.J.L. Global Burden of Disease Cancer Collaboration Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017.JAMA Oncol.20195121749176810.1001/jamaoncol.2019.299631560378
     [Google Scholar]
  8. DingK. ZhangF. QiG. LinM. ChenM. ChenY. ZhengJ. ZhouF. ZFP36L1 promotes gastric cancer progression via regulating JNK and p38 MAPK signaling pathways.Recent Patents Anticancer Drug Discov.2023181809110.2174/157489281766622052410240335611776
     [Google Scholar]
  9. SiegelR.L. MillerK.D. WagleN.S. JemalA. Cancer statistics, 2023.CA Cancer J. Clin.2023731174810.3322/caac.2176336633525
     [Google Scholar]
  10. KatzkaD.A. KahrilasP.J. Advances in the diagnosis and management of gastroesophageal reflux disease.BMJ2020371m378610.1136/bmj.m378633229333
     [Google Scholar]
  11. VogelaarI.P. van der PostR.S. BisselingT.M. van KriekenJ.H.J.M. LigtenbergM.J.L. HoogerbruggeN. Familial gastric cancer: Detection of a hereditary cause helps to understand its etiology.Hered. Cancer Clin. Pract.20121011810.1186/1897‑4287‑10‑1823231819
     [Google Scholar]
  12. FerroA. RosatoV. RotaM. CostaA.R. MoraisS. PelucchiC. JohnsonK.C. HuJ. PalliD. FerraroniM. ZhangZ.F. BonziR. YuG.P. PeleteiroB. López-CarrilloL. TsuganeS. HamadaG.S. HidakaA. ZaridzeD. MaximovitchD. VioqueJ. Navarrete-MunozE.M. AragonésN. MartínV. Hernández-RamírezR.U. BertuccioP. WardM.H. MalekzadehR. PourfarziF. MuL. López-CervantesM. PersianiR. KurtzR.C. LagiouA. LagiouP. BoffettaP. BocciaS. NegriE. CamargoM.C. CuradoM.P. La VecchiaC. LunetN. Meat intake and risk of gastric cancer in the Stomach cancer Pooling (StoP) project.Int. J. Cancer20201471455510.1002/ijc.3270731584199
     [Google Scholar]
  13. SmythE.C. NilssonM. GrabschH.I. van GriekenN.C.T. LordickF. Gastric cancer.Lancet20203961025163564810.1016/S0140‑6736(20)31288‑532861308
     [Google Scholar]
  14. Japanese Gastric Cancer AssociationJapanese gastric cancer treatment guidelines 2014 (ver. 4).Gastric Cancer201720111910.1007/s10120‑016‑0622‑427342689
     [Google Scholar]
  15. Al-BatranS.E. HomannN. PauligkC. GoetzeT.O. MeilerJ. KasperS. KoppH.G. MayerF. HaagG.M. LuleyK. LindigU. SchmiegelW. PohlM. StoehlmacherJ. FolprechtG. ProbstS. PrasnikarN. FischbachW. MahlbergR. TrojanJ. KoenigsmannM. MartensU.M. Thuss-PatienceP. EggerM. BlockA. HeinemannV. IllerhausG. MoehlerM. SchenkM. KullmannF. BehringerD.M. HeikeM. PinkD. TeschendorfC. LöhrC. BernhardH. SchuchG. RethwischV. von WeikersthalL.F. HartmannJ.T. KnebaM. DaumS. SchulmannK. WenigerJ. BelleS. GaiserT. OduncuF.S. GüntnerM. HozaeelW. ReichartA. JägerE. KrausT. MönigS. BechsteinW.O. SchulerM. SchmalenbergH. HofheinzR.D. FLOT4-AIO Investigators Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Lancet2019393101841948195710.1016/S0140‑6736(18)32557‑130982686
     [Google Scholar]
  16. FergusonF.M. GrayN.S. Kinase inhibitors: The road ahead.Nat. Rev. Drug Discov.201817535337710.1038/nrd.2018.2129545548
     [Google Scholar]
  17. FuchsC.S. DoiT. JangR.W. MuroK. SatohT. MachadoM. SunW. JalalS.I. ShahM.A. MetgesJ.P. GarridoM. GolanT. MandalaM. WainbergZ.A. CatenacciD.V. OhtsuA. ShitaraK. GevaR. BleekerJ. KoA.H. KuG. PhilipP. EnzingerP.C. BangY.J. LevitanD. WangJ. RosalesM. DalalR.P. YoonH.H. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer.JAMA Oncol.201845e18001310.1001/jamaoncol.2018.001329543932
     [Google Scholar]
  18. DewsonG. EichhornP.J.A. KomanderD. Deubiquitinases in cancer.Nat. Rev. Cancer2023231284286210.1038/s41568‑023‑00633‑y37935888
     [Google Scholar]
  19. RenJ. YuP. LiuS. LiR. NiuX. ChenY. ZhangZ. ZhouF. ZhangL. Deubiquitylating enzymes in cancer and immunity.Adv. Sci. (Weinh.)20231036230380710.1002/advs.20230380737888853
     [Google Scholar]
  20. WangA. HuangH. ShiJ.H. YuX. DingR. ZhangY. HanQ. NiZ.Y. LiX. ZhaoR. ZouQ. USP47 inhibits m6A-dependent c-Myc translation to maintain regulatory T cell metabolic and functional homeostasis.J. Clin. Invest.202313323e16936510.1172/JCI16936537788092
     [Google Scholar]
  21. DagarG. KumarR. YadavK.K. SinghM. PanditaT.K. Ubiquitination and deubiquitination: Implications on cancer therapy.Biochim. Biophys. Acta. Gene Regul. Mech.20231866419497910.1016/j.bbagrm.2023.19497937633647
     [Google Scholar]
  22. ZhengL.L. WangL.T. PangY.W. SunL.P. ShiL. Recent advances in the development of deubiquitinases inhibitors as antitumor agents.Eur. J. Med. Chem.202426611616110.1016/j.ejmech.2024.11616138262120
     [Google Scholar]
  23. GaoH. YinJ. JiC. YuX. XueJ. GuanX. ZhangS. LiuX. XingF. Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application.J. Exp. Clin. Cancer Res.202342122510.1186/s13046‑023‑02805‑y37658402
     [Google Scholar]
  24. AnT. LuY. GongZ. WangY. SuC. TangG. HouJ. Research progress for targeting deubiquitinases in gastric cancers.Cancers (Basel)20221423583110.3390/cancers1423583136497313
     [Google Scholar]
  25. LiK.Q. BaiX. KeA.T. DingS.Q. ZhangC.D. DaiD.Q. Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer.Biomed. Pharmacother.202417311632310.1016/j.biopha.2024.11632338401523
     [Google Scholar]
  26. DouN. HuQ. LiL. WuQ. LiY. GaoY. USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2.Int. J. Biol. Sci.20201691648165710.7150/ijbs.4311732226309
     [Google Scholar]
  27. ZhengZ. ShangY. XuR. YanX. WangX. CaiJ. BaiZ. LiuX. YinJ. ZhangJ. ZhangZ. Ubiquitin specific peptidase 38 promotes the progression of gastric cancer through upregulation of fatty acid synthase.Am. J. Cancer Res.20221262686269635812059
     [Google Scholar]
  28. HouK. ZhuZ. WangY. ZhangC. YuS. ZhuQ. YanB. Overexpression and biological function of ubiquitin-specific protease 42 in gastric cancer.PLoS One2016113e015299710.1371/journal.pone.015299727030989
     [Google Scholar]
  29. TuR. KangY. PanY. DaY. RenD. ZhangR. CaiZ. LiuY. XuJ. MaJ. ZhouZ. YinS. LiX. ZhangP. ZhangQ. WangJ. LuX. ZhangC. USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer.Cancer Cell Int.20242413310.1186/s12935‑024‑03224‑538233848
     [Google Scholar]
  30. ZhangC. WangH. LiuQ. DaiS. TianG. WeiX. LiX. ZhaoL. ShanB. LncRNA CCAT1 facilitates the progression of gastric cancer via PTBP1-mediated glycolysis enhancement.J. Exp. Clin. Cancer Res.202342124610.1186/s13046‑023‑02827‑637740243
     [Google Scholar]
  31. KimS.H. BaekK.H. Regulation of cancer metabolism by deubiquitinating enzymes: The warburg effect.Int. J. Mol. Sci.20212212617310.3390/ijms2212617334201062
     [Google Scholar]
  32. XieY WangM XiaM GuoY ZuX ZhongJ Ubiquitination regulation of aerobic glycolysis in cancer.Life Sci.202229212032210.1016/j.lfs.2022.120322
     [Google Scholar]
  33. WarburgO. On the origin of cancer cells.Science1956123319130931410.1126/science.123.3191.30913298683
     [Google Scholar]
  34. ShengH. TangW. Glycolysis inhibitors for anticancer therapy: A review of recent patents.Recent Patents Anticancer Drug Discov.201611329730810.2174/157489281166616041516010427087655
     [Google Scholar]
  35. LiW. SunX. Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments.Recent Patents Anticancer Drug Discov.201813445546810.2174/157489281366618083110251930173649
     [Google Scholar]
  36. LvT. ZhangB. JiangC. ZengQ. YangJ. ZhouY. USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation.Int. J. Oncol.202363411310.3892/ijo.2023.556137594129
     [Google Scholar]
  37. XiaP. ZhangH. LuH. XuK. JiangX. JiangY. GongyeX. ChenZ. LiuJ. ChenX. MaW. ZhangZ. YuanY. METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.Cancer Commun. (Lond.)202343333836410.1002/cac2.1240336602428
     [Google Scholar]
  38. WuH. GuoX. JiaoY. WuZ. LvQ. TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect.Int. J. Oncol.202261614410.3892/ijo.2022.543436196894
     [Google Scholar]
  39. ZhangX. GengL. TangY. WangY. ZhangY. ZhuC. LeiH. XuH. ZhuQ. WuY. GuW. Ubiquitin-specific protease 14 targets PFKL-mediated glycolysis to promote the proliferation and migration of oral squamous cell carcinoma.J. Transl. Med.202422119310.1186/s12967‑024‑04943‑z38388430
     [Google Scholar]
  40. GaoS. WangY. XuY. LiuL. LiuS. USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis.Biochim. Biophys. Acta Mol. Basis Dis.20241870316701110.1016/j.bbadis.2023.16701138176460
     [Google Scholar]
  41. XuX. ChenY. ShaoS. WangJ. ShanJ. WangY. WangY. ChangJ. ZhouT. ChenR. LiuS. LiC. LiC. LiX. USP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma.Int. J. Biol. Sci.20242041492150810.7150/ijbs.9077438385089
     [Google Scholar]
  42. WengN. ZhouC. ZhouY. ZhongY. JiaZ. RaoX. QiuH. ZengG. JinX. ZhangJ. ZhuangZ. LiangZ. DengY. LiQ. YangS. LuoH. WangH. WuX. IKZF4/NONO-RAB11FIP3 axis promotes immune evasion in gastric cancer via facilitating PD-L1 endosome recycling.Cancer Lett.202458421661810.1016/j.canlet.2024.21661838211652
     [Google Scholar]
  43. SpanoD. CataraG. Targeting the ubiquitin–proteasome system and recent advances in cancer therapy.Cells20231312910.3390/cells1301002938201233
     [Google Scholar]
  44. XiaoY. LiuR. LiN. LiY. HuangX. Role of the ubiquitin–proteasome system on macrophages in the tumor microenvironment.J. Cell. Physiol.20242392e3118010.1002/jcp.3118038219045
     [Google Scholar]
  45. ZhangD. YangG. ZhangL. WuM. SuR. The efficacy and mechanism of proteasome inhibitors in solid tumor treatment.Recent Patents Anticancer Drug Discov.202217326828310.2174/157489281666621120215453634856915
     [Google Scholar]
  46. KasturiranganS. NancarrowD.J. ShahA. LagisettyK.H. LawrenceT.S. BeerD.G. RayD. Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.Cell Death Dis.202415319410.1038/s41419‑024‑06575‑z38453895
     [Google Scholar]
  47. LiangX. RenH. HanF. LiangR. ZhaoJ. LiuH. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology.Med. Res. Rev.202310.1002/med.2199237983964
     [Google Scholar]
  48. ParkH.B. BaekK.H. Current and future directions of USP7 interactome in cancer study.Biochim. Biophys. Acta Rev. Cancer20231878618899210.1016/j.bbcan.2023.18899237775071
     [Google Scholar]
  49. CruzL. SoaresP. CorreiaM. Ubiquitin-specific proteases: Players in cancer cellular processes.Pharmaceuticals (Basel)202114984810.3390/ph1409084834577547
     [Google Scholar]
  50. KimSB HwangS ChaJY LeeHJ Programmed death ligand 1 regulatory crosstalk with ubiquitination and deubiquitination: Implications in cancer immunotherapy.Int J Mol Sci.202425510.3390/ijms25052939
     [Google Scholar]
  51. TzimasC. MichailidouG. ArsenakisM. KieffE. MosialosG. HatzivassiliouE.G. Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-κB.Cell. Signal.2006181839210.1016/j.cellsig.2005.03.01716214042
     [Google Scholar]
  52. LockhartP.J. HulihanM. LincolnS. HusseyJ. SkipperL. BisceglioG. WilkesK. FarrerM.J. Identification of the human ubiquitin specific protease 31 (USP31) gene: structure, sequence and expression analysis.DNA Seq.200415191410.1080/1085566031000163819715354349
     [Google Scholar]
  53. YeS. LawlorM.A. Rivera-ReyesA. EgolfS. ChorS. PakK. CiottiG.E. LeeA.C. MarinoG.E. ShahJ. NiedzwickiD. WeberK. ParkP.M.C. AlamM.Z. GrazioliA. HaldarM. XuM. PerryJ.A. QiJ. Eisinger-MathasonT.S.K. YAP1-mediated suppression of USP31 enhances NFκB activity to promote sarcomagenesis.Cancer Res.201878102705272010.1158/0008‑5472.CAN‑17‑405229490948
     [Google Scholar]
  54. HouY. FanY. XiaX. PanJ. HouJ. LiuX. ChenX. USP31 acetylation at Lys1264 is essential for its activity and cervical cancer cell growth.Acta Biochim. Biophys. Sin. (Shanghai)20215381037104310.1093/abbs/gmab08034184746
     [Google Scholar]
  55. QiaoX ZhangY SunL Association of human breast cancer CD44(-)/CD24(-) cells with delayed distant metastasis.Elife20211010.7554/eLife.65418
     [Google Scholar]
  56. YuY. ChenG. JiangC. GuoT. TangH. YuanZ. WangY. TanX. ChenJ. ZhangE. WangX. USP31 serves as a potential biomarker for predicting prognosis and immune responses for clear cell renal cell carcinoma via single-cell and bulk RNA-sequencing.J. Gene Med.2024261e359410.1002/jgm.359437699648
     [Google Scholar]
  57. LiangW. YangM. WangX. QianY. GaoR. ShiY. ShiX. ShiL. XuT. ZhangQ. Deubiquitylase USP31 induces autophagy and promotes the progression in lung squamous cell carcinoma cells by stabilizing E2F1 expression.Curr. Cancer Drug Targets20242410.2174/011568009626455723112410205438204265
     [Google Scholar]
  58. XuL. XiangW. YangJ. GaoJ. WangX. MengL. YeK. ZhaoX.H. ZhangX.D. JinL. YeY. PHB2 promotes SHIP2 ubiquitination via the E3 ligase NEDD4 to regulate AKT signaling in gastric cancer.J. Exp. Clin. Cancer Res.20244311710.1186/s13046‑023‑02937‑138200519
     [Google Scholar]
  59. WangJ. XiangY. FanM. FangS. HuaQ. The ubiquitin–proteasome system in tumor metabolism.Cancers (Basel)2023158238510.3390/cancers1508238537190313
     [Google Scholar]
  60. JiangY. NiS. XiaoB. JiaL. Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy.Acta Pharm. Sin. B202313114341437210.1016/j.apsb.2023.07.01937969742
     [Google Scholar]
  61. JiangX. PengQ. PengM. OyangL. WangH. LiuQ. XuX. WuN. TanS. YangW. HanY. LinJ. XiaL. TangY. LuoX. DaiJ. ZhouY. LiaoQ. Cellular metabolism: A key player in cancer ferroptosis.Cancer Commun. (Lond.)202444218520410.1002/cac2.1251938217522
     [Google Scholar]
  62. BerrellN. SadeghiradH. BlickT. BidgoodC. LeggattG.R. O’ByrneK. KulasingheA. Metabolomics at the tumor microenvironment interface: Decoding cellular conversations.Med. Res. Rev.2023med.2201010.1002/med.2201038146814
     [Google Scholar]
  63. WangJ. FangY. LiuT. TRIM32 promotes the growth of gastric cancer cells through enhancing AKT activity and glucose transportation.BioMed Res. Int.2020202011010.1155/2020/402762732051827
     [Google Scholar]
  64. HuangZ. HuangS. Reposition of the fungicide ciclopirox for cancer treatment.Recent Patents Anticancer Drug Discov.202116212213510.2174/157489281666621021109084533573561
     [Google Scholar]
  65. ChenX. LiuB. TongJ. BoJ. FengM. YinL. LinX. Chlorogenic acid inhibits proliferation, migration and invasion of pancreatic cancer cells via AKT/GSK-3β/β-catenin signaling pathway.Recent Patents Anticancer Drug Discov.202419214615310.2174/157489281866623032713474638214354
     [Google Scholar]
  66. LiB. XiongX. XuJ. PengD. NieG. WenN. WangY. LuJ. METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.Oncogene202410.1038/s41388‑024‑02970‑038374407
     [Google Scholar]
  67. ZarriziR. MenardJ.A. BeltingM. MassoumiR. Deubiquitination of γ-tubulin by BAP1 prevents chromosome instability in breast cancer cells.Cancer Res.201474226499650810.1158/0008‑5472.CAN‑14‑022125228651
     [Google Scholar]
  68. GurzuS. BaniasL. BaraT. iF. BaraT. JungI. The epithelial-mesenchymal transition pathway in two cases with gastric metastasis originating from breast carcinoma, one with a metachronous primary gastric cancer.Recent Patents Anticancer Drug Discov.201813111812410.2174/221279840966617110112110829090670
     [Google Scholar]
  69. WangY. ZhengL. ShangW. YangZ. LiT. LiuF. ShaoW. LvL. ChaiL. QuL. XuQ. DuJ. LiangX. ZengJ. JiaJ. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer.Cell Death Differ.202229112190220210.1038/s41418‑022‑01008‑w35534546
     [Google Scholar]
  70. PengY. XuY. ZhangX. DengS. YuanY. LuoX. HossainM.T. ZhuX. DuK. HuF. ChenY. ChangS. FengX. FanX. AshktorabH. SmootD. MeltzerS.J. HouG. WeiY. LiS. QinY. JinZ. A novel protein AXIN1-295aa encoded by circAXIN1 activates the Wnt/β-catenin signaling pathway to promote gastric cancer progression.Mol. Cancer202120115810.1186/s12943‑021‑01457‑w34863211
     [Google Scholar]
  71. SeatonG. SmithH. BrancaleA. WestwellA.D. ClarksonR. Multifaceted roles for BCL3 in cancer: A proto-oncogene comes of age.Mol. Cancer2024231710.1186/s12943‑023‑01922‑838195591
     [Google Scholar]
  72. RahmaniF. Mohammed Al-AsadyA. HanaieR. ZandigoharM. FaridnejadH. PayazdanM. SafaviP. RyzhikovM. HassanianS.M. Interplay between lncRNA/miRNA and Wnt/ß-catenin signaling in brain cancer tumorigenesis.EXCLI J.2023221211122210.17179/excli2023‑649038204968
     [Google Scholar]
  73. TsukiyamaT. New insights in ubiquitin-dependent Wnt receptor regulation in tumorigenesis. In Vitro Cell. Dev. Biol. Anim.202410.1007/s11626‑024‑00855‑w38383910
     [Google Scholar]
  74. WuX.T. WangY.H. CaiX.Y. DongY. CuiQ. ZhouY.N. YangX.W. LuW.F. ZhangM. RNF115 promotes lung adenocarcinoma through Wnt/β-catenin pathway activation by mediating APC ubiquitination.Cancer Metab.202191710.1186/s40170‑021‑00243‑y33509267
     [Google Scholar]
  75. TotlandM.Z. OmoriY. SørensenV. KryeziuK. AasenT. BrechA. LeitheE. Endocytic trafficking of connexins in cancer pathogenesis.Biochim. Biophys. Acta Mol. Basis Dis.20231869716681210.1016/j.bbadis.2023.16681237454772
     [Google Scholar]
/content/journals/pra/10.2174/0115748928297343240425055552
Loading
USP31 Activates the Wnt/β-catenin Signaling Pathway and Promotes Gastric Cancer Cell Proliferation, Invasion and Migration
Recent Patents on Anti-Cancer Drug Discovery 20, 232 (2025); https://doi.org/10.2174/0115748928297343240425055552
/content/journals/pra/10.2174/0115748928297343240425055552
/content/journals/pra/10.2174/0115748928297343240425055552
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Gastric cancer; qRT-PCR; ubiquitination; USP31; western blotting; Wnt/β-catenin pathway

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test